NeoMPS S.A. — Company Profile

NeoMPS SA 7, rue de Boulogne 67100 Strasbourg France Tel.: +33 (0)3 88 79 08 79 Fax: +33 (0)3 88 79 18 56 Email: neo@neomps.com Website: http://www.neomps.com/

NeoMPS provides a full spectrum of products and services in the field of custom peptide synthesis for research and development, amino acids, peptide building blocks and custom organic synthesis, as well as GMP manufacturing.

Since its creation in 1986, NeoMPS SA has been in perpetual evolution, consistently adapting operations to meet the always expanding needs of its customers.

NeoMPS SA has supplied over 35.000 different products in milligram to gram quantities to the scientific community, acquiring a great deal of expertise in the manufacture of unusual amino acids, peptides and peptide derivatives.

In 1998, our GMP production facility became fully functional enabling us to supply hundreds of grams to kilogram quantities of Active Pharmaceutical Ingredients (APIs) to biopharmaceutical companies around the world.

From the beginning, our goal at NeoMPS SA is to provide a full spectrum of technologies of products and services. We offer custom peptide synthesis for research and development, amino acids, peptide building blocks, custom organic synthesis and GMP manufacturing.

Nearly one thousand regular customers worlwide trust our company and can attest to our reliability. This is the result of good technology placed in well-qualified hands enhanced by the dedication our people bring to their work.

Now with two facilities on two different continents: NeoMPS, Inc. in California, USA, and NeoMPS SA in France are united to serve you with separate geographical distributions and complementary capabilities.



Source: NeoMPS

[Read more!]

Polyplus-transfection S.A. — Company Profile

Polyplus-transfection SA BIOPARC Boulevard Sébastien Brant BP 90018 67400 Illkirch France Tel.: +33 (0)3 90 40 61 80 Fax : +33 (0)3 90 40 61 81 Website: http://www.polyplus-transfection.com/

Polyplus-transfection is a research-focused biotechnology company developing and marketing innovative solutions for transfection and therapies based on nucleic acid delivery.

Transfection allows the introduction of nucleic acids, such as a gene or small interfering RNA (siRNA), into cells using chemical compounds. The technique is widely used in experimental research and in protein production.

Introducing a gene into a cell nucleus triggers the expression of the corresponding protein. Conversely, transferring siRNA will block the production of a protein. Inappropriate gene expression is the root cause of numerous diseases. As a result, the ability to control those genes through gene therapy or RNA interference opens up new therapeutic approaches where efficient intra-cellular drug transfer is key to success.

Using its know-how in nucleic acid delivery, the R&D department at Polyplus-transfection is focused on the development of innovative synthetic compounds designed to take account of the latest advances in the transfer of biomolecules, especially the in vivo delivery of small interfering RNA. Polyplus-transfection is one of the technology leaders in the transfection market.

Polyplus-transfection has established a number of R&D partnerships with biotechnology companies involved in therapeutics. It also plays an active role in European research networks such as GIANT (Gene therapy, and Integrated Approach to Neoplastic Treatment) and RIGHT (RNA Interference Technology as Human Therapeutic Tool). Polyplus-transfection recently extended its field of expertise to the development of new cationic oligonucleotides, ZNA (Zip Nucleic Acid), for molecular biology and diagnostics.


Source: Polyplus-transfection

[Read more!]

Transgène S.A. — Company Profile

Transgène S.A. Head office & Laboratory 11, rue de Molsheim 67082 Strasbourg Cedex France Tel.: +33 (0)3 88 27 91 00 Email: communication@transgene.fr Website: http://www.transgene.fr/

Transgene is a biopharmaceutical company dedicated to the discovery and development of gene-based therapeutic vaccines and immunotherapy products for the treatment of cancer and infectious diseases.

Transgene's business strategy is to develop therapeutic vaccines against cancer and infectious diseases based on its broad technology platform for gene delivery. Transgene implements this strategy in three different ways:

• by developing vaccines and products in specific indications and partnering with pharmaceutical companies for later stage development;
• by independently developing and commercializing vaccines and products for certain special markets;
• by licensing vector technologies to companies with proprietary genes for short and medium term revenues.

Source: Transgène

[Read more!]